Chemotherapy in BC patients Aged ≥70 with High Tumour Grade

[Hazelgreen]

Published in Oncology

Journal Scan / Research · July 02, 2022

Adding Chemotherapy to Endocrine Therapy After Surgery in Women Aged ≥70 Years With ER+/HER2− Breast Cancer and a High Genomic Grade Index

Journal of Clinical Oncology

TAKE-HOME MESSAGE

This phase III trial showed no statistically significant overall survival (OS) benefit with the addition of chemotherapy to endocrine therapy (ET) after surgery in patients older than 70 years with ER+, HER2− breast cancer with a high tumor genomic grade index (GGI).

GGI is not predictive of OS benefits with chemotherapy added to ET in this patient population.

– Jing Xi, MD, MPH

[Hazelgreen]

My personal point-of-view is that chemotherapy has the potential to do more damage than good, especially in seniors.

[Threadsgirl in reply to Hazelgreen]

By chemotherapy did they mean oral or IV meds? I also hold the view from personal experience that “strong” chemo can be harmful to older people, especially with long term side effects. It would be a tough call though to not offer someone a treatment that is out there, I think most people would want to try whatever is in the arsenal.

[Hazelgreen in reply to Hazelgreen]

I forgot to add the link to the original abstract: ascopubs.org/doi/abs/10.120....

The chemotherapy provided was: "Investigators chose between 3 CT regimens: 4 cycles of doxorubicin/cyclophosphamide, non-pegylated liposomal doxorubicin/cyclophosphamide or docetaxel/cyclophosphamide, given q3w with G-CSF." These choices were compared to: "Standard ET consisted of 5 years of aromatase inhibitor, tamoxifen or a sequence based on tolerance."